EZH2 inhibitors (EZH2i) have been shown to reduce tumor growth and promote apoptosis and autophagy in preclinical models across different tumor histologic types characterized by the presence of EZH2-activating mutations or altered EZH2 expression. This evidence concerns the gene EZH2 and neoplasm.